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Abstract: The aim of this study was to verify the reliability of a next generation sequencing
(NGS)-based method as a strategy to detect all possible BRCA mutations, including large genomic
rearrangements. Genomic DNA was obtained from a peripheral blood sample provided by
a patient from Southern Italy with early onset breast cancer and a family history of diverse cancers.
BRCA molecular analysis was performed by NGS, and sequence data were analyzed using two
software packages. Comparative genomic hybridization (CGH) array was used as confirmatory
method. A novel large duplication, involving exons 4–26, of BRCA2 was directly detected in the
patient by NGS workflow including quantitative analysis of copy number variants. The duplication
observed was also found by CGH array, thus confirming its extent. Large genomic rearrangements
can affect the BRCA1/2 genes, and thus contribute to germline predisposition to familial breast and
ovarian cancers. The frequency of these mutations could be underestimated because of technical
limitations of several routinely used molecular analysis, while their evaluation should be included
also in these molecular testing. The NGS-based strategy described herein is an effective procedure to
screen for all kinds of BRCA mutations.
Keywords: hereditary breast cancer; BRCA2; large genomic rearrangements; next generation
sequencing; aCGH
1. Introduction
Germline mutations in the BRCA genes confer an increased risk for breast and ovarian cancers [1].
In fact, about 15% of all breast cancer cases fall within the hereditary breast and ovarian cancer
(HBOC) syndrome, and BRCA1 and BRCA2 are the two major HBOC susceptibility genes identified so
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far [2]. BRCA mutations carriers have a higher lifetime risk of different types of cancers, which often
occur at an earlier age with respect to the general population [1,2]. Consequently, carriers’ early
identification is important to offer patients and their families the most appropriate surveillance
screening and prophylactic, therapeutic or surgical options [3–5]. Given the large size of both BRCA1
and BRCA2 genes and the absence of mutational hot spots, highly sensitive methods are required
for the molecular analysis of the BRCA genes [6]. Most of the known BRCA1/2 mutations are single
nucleotide substitutions or small insertions/deletions (https://research.nhgri.nih.gov/projects/bic/),
easily detectable by DNA sequencing methods. However, generally these methods are not able to
identify large genomic rearrangements (LGRs) [7].
LGRs, including deletions, duplications or insertions larger than 500 kb, have been identified in
the BRCA genes, with a frequency between 0 and 28% depending on the population analyzed [7–11].
These mutations appear to be more frequent in the BRCA1 gene, probably due to the higher frequency
of Alu sequences in this gene and/or due to homologous recombination events between BRCA1 and
its pseudogene [7–11]. To date, various methods have been used to identify LGR in the BRCA genes,
namely Southern blot, quantitative PCR, and multiplex ligation probes amplification [7–11]. Thus far,
81 and 24 different LGRs have been reported in BRCA1 and BRCA2, respectively [9,12]. Consequently,
LGRs account for a not negligible proportion of BRCA mutations, and their investigation should be
included in BRCA genes molecular analysis workflow.
Thanks to advances made in next-generation sequencing (NGS) methods, these procedures
have shown their potentiality for molecular analysis at DNA level and are now widely used in
the clinical setting, such as for BRCA genes testing [6,13–16]. Since these technologies generate
millions of sequences of the same target genomic region, it is likely that, coupled with the appropriate
bioinformatics tools, the analysis of quantitative sequencing reads can be used to estimate LGRs [17,18].
Here, we report a large duplication of the BRCA2 gene identified in an Italian HBOC family by
NGS and confirmed by array-based comparative genomic hybridization (aCGH). Our findings indicate
that NGS-based methods can be an effective strategy with which to analyze BRCA1/2 mutations,
which also include LGRs. The large-scale use of this approach will lead possibly to an increase in
the number of LGRs in BRCA1/2 genes, and to better assess their contribution to the risk of HBOC
predisposition in predictive medicine, which is also appropriate for medical decision.
2. Results
In the NGS-based analysis of the BRCA genes, we sequenced 69,979 read pairs, of which 69,883
(corresponding to 99.86% of all reads) were successfully mapped. We did not find any low coverage
regions, defined as regions that fall within amplicons but have a coverage less than 50X (Figure 1).
Furthermore, the sequence coverage found in all our amplicons belonging to our patient was at
least 100X for all the regions. Both the software we used confirmed the absence of pathogenic point
mutations in our patient. Instead, the CNV analysis with the second described software highlighted
a low-noise status and a very large duplication (duplication ratio = 3) in high-confidence status in the
BRCA2 gene (13: 32,899,089-32,971,294) involving about 72,205 bp (Figure 2a–c).
In the BRCA2 region predicted to be duplicated, we identified 8 SNPs: 3 were homozygous
while the other 5 were present in heterozygous status (Supplementary Materials Table S1).
Usually, in a wild-type diploid asset, the reads distribution for a heterozygous variant ranges from 45%
to 55% of all the obtained reads covering that variant. This corresponds to the fact that one allele carries
the variant and the other does not. In our patient, no one of the five variants detected as heterozygous
has this kind of frequency: 3 have a frequency higher than expected, ranging from 64–67%, and 2 have
a frequency lower than expected (36–37%). This finding supports the presence of the duplicated allele:
assuming that we are simultaneously analyzing 3 alleles, each of them accounts for about 33% of
all the reads. Thus, variants occurring on the wild type allele will have a frequency of about 33%,
while variants occurring in the duplicated allele will have a frequency of about 66%: these are exactly
the values we found in our patient.
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As shown in Figure 2d, aCGH analysis of our patient highlighted a heterozygous
amplification on chromosome 13 at the q13.1 region of the BRCA2 gene, namely, chr13.hg19:g.
(32,897,658-32,897,717)–(32,969,954-32,970,004) amp (range between 72,296 and 72,287 bp). The exact
breakpoints of the duplication insertion should be searched in detail by other techniques.
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Figure 1. Next generation sequencing coverage of the BRCA2 gene. (a) The relative position of the 
BRCA2 gene on chromosome 13. (b) The patient’s coverage for each sequenced amplicon is reported 
with respect to BRCA2 exons at the bottom. 
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BRCA2 gene on chromosome 13. (b) The patient’s coverage for each sequenced amplicon is reported
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chromosome 13. This analysis shows heterozygous amplification in 13q13.1 of about 72 kb involving 
the BRCA2 gene. Green and red dots represent the log2 fluorescence ratios of individual 
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Figure 2. Large BRCA2 gene duplication. (a) Gene view of the global copy number variant (CNV)
analysis of the BRCA1 and BRCA2 genes. The noise is low for both genes. BRCA1 contains no CNVs
in any of the target amplicons, while BRCA2 presents a large duplication, from exon 4 to exon 26.
(b) The CNV analysis of the BRCA2 gene. b1 BRCA2 with all the exons; b2 CNV target regions for all the
5 plexes of the MASTR BRCA DX (Multiplicom); b3 CNV confidence plot showing a high confidence
for almost all target amplicons. (c) Sample graph for each amplicon in BRCA2 showing the large
duplication. There is an undetermined region for the amplicon 11_06 probably due to a region difficult
to analyze. (d) Array-based comparative genomic hybridization (a-CGH) profile of chromosome 13.
This analysis shows heterozygous amplification in 13q13.1 of about 72 kb involving the BRCA2 gene.
Green and red dots represent the log2 fluorescence ratios of individual oligonucleotide probes on
the microarrays; red dots represent probes with positive log2 fluorescence ratios, whereas green dots
represent probes with negative log2 fluorescence ratios.
3. Discussion
Here, we report the identification of a large novel BRCA2 duplication in an HBOC patient obtained
using an NGS-based method. The tested patient is a 43-year-old woman from Southern Italy who
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had an early onset breast cancer (under 40 years of age). Since she has a family history suggestive
of hereditary cancer, after genetic counseling, she underwent BRCA molecular testing to verify her
mutational status. We previously assessed the efficacy of an NGS-based approach for the fast detection
of BRCA point mutations and small insertions/deletions [6]. Since, in principle, NGS can be used
also for quantitative analysis and, thus, overcome a typical limitation of DNA sequencing analysis
by detecting also LGRs, we assessed this hypothesis in our case report. In our patient, no pathogenic
point mutations were identified in BRCA1 or in BRCA2. Instead, bioinformatics analysis of LGRs
revealed a large duplication in BRCA2 involving exons 4–26, whose presence was confirmed by a-CGH
analysis. Hitherto, BRCA LGRs have been considered rare events and, only a few BRCA2 LGRs have
been characterized [7–12,17].
Our data reinforce the concept that the frequency of BRCA LGRs is probably underestimated
since they elude currently used diagnostic strategies, which include only point mutations or small
indels [7–12,17]. Furthermore, other methods for CNV detection require additional diagnostic
workflows, thereby increasing the time to results and also the costs of the molecular tests. Here, we have
assessed the reliability of a NGS-based BRCA genes analysis to simultaneously detect most of the
possible pathogenic mutations affecting these genes, including LGRs. Indeed, the possibility to have
a unique method for the fast and accurate detection of all the possible genetic variants affecting
a gene of interest, including LGRs, is a goal of molecular diagnostics, also in the field of BRCA genes
evaluation. Consequently, this is actually a very hot topic since previous studies lack data regarding
LGRs detection [7–12,17]; certainly, NGS give the opportunity to fill-in this gap. Even if we report
just one case, we believe that our results reinforce the need to include LGRs screening in the BRCA
routine assessment on one side. In addition, we describe a very rapid and accurate procedure and,
finally and not less important, we also report a novel, not previously detected large BRCA2 duplication.
The results obtained in our case report demonstrate that such a NGS-based analysis could serve as
a cancer risk prediction tool able to detect point mutations and small insertions/deletions, and also
to highlight those patients carrying known and unknown LGRs. This strategy not only optimizes
laboratory settings since only one molecular workflow is required, but, by enlarging the spectrum
of mutations detected, also increases the diagnostic sensitivity of the molecular test. Finally, the
application of this strategy in large-scale population studies will shed light on the frequency of BRCA
LGRs in HBOC patients.
Note after Discussion
While this paper was under our internal revision, Concolino et al. [19] reported a large duplication
in BRCA2, not very different to the novel one we describe in this manuscript. We plan to study our
case report in greater depth to evaluate the possibility that this duplication may occur in an easier
mutational event area. It is noteworthy that our results were obtained using a different methodological
NGS approach with a pipeline analysis of a single workflow that results in a fast turn-around time and
with a bioinformatics tool that simultaneously analyzes sequences for CNVs evaluation.
4. Materials and Methods
4.1. Enrollment of Patients and Collection of Samples
The patient, now 43 years old, was enrolled from among those attending the Oncology Division,
Department of Clinical Medicine and Surgery, of the University of Naples “Federico II”, Naples, Italy.
She was diagnosed with early onset breast cancer and had a positive family history for breast, colon,
prostate and ovarian cancers (Figure 3).
Int. J. Mol. Sci. 2017, 18, 2487 6 of 9
Int. J. Mol. Sci. 2017, 18, 2487 6 of 9 
 
 
Figure 3. Pedigree of the patient. Our patient (III.3) is indicated by the arrow. Breast, ovarian, colon 
and prostate cancers are reported in the family. D.: age of death; y.o.: years old. 
According to the National Comprehensive Cancer Network guidelines [20], pre-test genetic 
counseling was carried out to evaluate the familial risk for HBOC and suggested molecular analysis 
be performed based on patient’s personal and familial history. All clinical data were collected and a 
three-generation family pedigree was constructed to report the number and the type of cancers 
present in the family (Figure 1). The patient gave her written informed consent to the molecular test. 
To date, the other unaffected members of the family, including the sisters and the brothers of the 
patient described herein, were not available for the molecular analysis to assess the presence of the 
BRCA2 familial mutation. 
Genomic DNA was isolated from a peripheral blood sample using the Maxwell® 16 LEV Blood 
DNA Kit (Promega Corporation, Madison, WI, USA) according to the manufacturer’s instructions, 
and eluted in molecular biology grade pure water. DNA quantity was evaluated using the 
NanoDrop 2000c Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA), while DNA 
quality was assessed by 0.8% agarose gel electrophoresis. 
4.2. Next Generation Sequencing 
The NGS analysis of the BRCA genes is described elsewhere [6]. Multiple amplicon DNA 
library, covering all the BRCA1 and BRCA2 coding and flanking intronic regions, was obtained using 
the BRCA MASTR Dx Assay kit (Multiplicom, Niel, Belgium), according to the manufacturer’s 
instructions. Sequencing reaction was carried out using the reagent kit V2 nano, 2 × 250PE, on the 
Illumina MiSeqSystem (Illumina Inc. San Diego, CA, USA), according to the manufacturer’s instructions. 
4.3. Bioinformatic Analysis 
The sequencing data were analyzed with two bioinformatics software: the SeqPilot software 
version 4.2 (JSI Medical Systems GmbH, Kippenheim, Germany) was used to detect point mutations, 
and the Sophia DDM® software version 4.2 (Sophia Genetics SA, Saint Sulpice, Switzerland) was 
used to confirm point mutations and to identify LGRs.  
Figure 3. Pedigree of the patient. Our patient (III.3) is indicated by the arrow. Breast, ovarian, colon
and prostate cancers are reported in the family. D.: age of death; y.o.: years old.
According to the National Comprehensive Cancer Network guidelines [20], pre-test genetic
counseling was carried out to evaluate the familial risk for HBOC and suggested molecular analysis
be performed based on patient’s personal and familial history. All clinical data were collected and
a three-generation family pedigree was constructed to report the number and the type of cancers
present in the family (Figure 1). The patient gave her written informed consent to the molecular test.
To date, the other unaffected members of the family, including the sisters and the brothers of the patient
described herein, were not available for the molecular analysis to assess the presence of the BRCA2
familial mutation.
Genomic DNA was isolated from a peripheral blood sample using the Maxwell® 16 LEV Blood
DNA Kit (Promega Corporation, Madison, WI, USA) according to the manufacturer’s instructions,
and eluted in molecular biology grade pure water. DNA quantity was evaluated using the NanoDrop
2000c Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA), while DNA quality was
assessed by 0.8% agarose gel electrophoresis.
4.2. Next Generation Sequencing
The NGS analysis of the BRCA genes is described elsewhere [6]. Multiple amplicon DNA library,
covering all the BRCA1 and BRCA2 coding and flanking intronic regions, was obtained using the BRCA
MASTR Dx Assay kit (Multiplicom, Niel, Belgium), according to the manufacturer’s instructions.
Sequencing reaction was carried out using the reagent kit V2 nano, 2 × 250PE, on the Illumina
MiSeqSystem (Illumina Inc. San Diego, CA, USA), according to the manufacturer’s instructions.
4.3. Bioinformatic Analysis
The sequencing data were analyzed with two bioinformatics software: the SeqPilot software
version 4.2 (JSI Medical Systems GmbH, Kippenheim, Germany) was used to detect point mutations,
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and the Sophia DDM® software version 4.2 (Sophia Genetics SA, Saint Sulpice, Switzerland) was used
to confirm point mutations and to identify LGRs.
The SeqNext module of the Sequence Pilot detects the variants present in each sample by
mapping the sequence reads against BRCA1 and BRCA2 reference sequences (the ENSG00000012048
gene reference and ENST00000357654.7 transcript from the Ensemble Database for BRCA1, and the
ENSG00000139618 gene reference and the ENST00000380152.7 transcript from the Ensemble Database
for BRCA2). The SeqNext module sorts the reads for each sample according to their index, and
a variant is called only if it is present in more than 15% of combined reads (both in forward
and reverse strands). If a variant occurs within a homopolymer (a sequence region with 6 or
more repeats of the same nucleotide), it is called only if its frequency exceeds 20% of reads.
The identified variants were characterized and classified according to their in silico gene function
predictions and biological significance using the Ensembl (http://www.ensembl.org/) and ClinVar
(https://www.ncbi.nlm.nih.gov/clinvar/) databases.
In addition to point mutation analysis, the Sophia DDM® software is also used to identify copy
number variants (CNVs) for LGR detection. In fact, it analyzes the coverage levels of the target regions
across all the samples that have been sequenced together. For each sample, the algorithm automatically
selects a set of reference samples that have similar coverage patterns in the same run. Based on the
reference samples, coverage is normalized by sample and by the target region, and CNVs are called
using a hidden-Markov-model algorithm, and thus the most probable copy-number for each target
region is determined. In presence of a wild type diploid asset a value of “2” is assigned to each amplicon
referring to the two alleles of autosomal genes. In the case of a deletion, corresponding to the loss of one
allele, a value of “1” will be assigned. Similarly, in the presence of a duplication a value of “3” will be
assigned to the duplicated amplicon referring to the additional copy. A confidence level is determined
at both sample and the target-region level. Samples are classified into “rejected”, “medium-noise”
and “low-noise” based on the residual coverage noise after normalization and CNV calling. No CNV
results are reported for rejected samples, but plots of the coverage profile of those samples are available
in the analysis output. After the analysis of CNVs, each amplicon in non-rejected samples are also
classified into three categories: “high-confidence”, “medium-confidence” and “undetermined”.
At the end of each data analysis, both software generate a report for each patient The SeqPilot
report shows point mutations and small indels, and contains information about the sequence-coverage
per exon. The Sophia DDM report shows the list of retained variants classified in 4 groups according to
their clinical significance (A, Most likely pathogenic; B, Potentially pathogenic; C, Variants of unknown
significance; and D, Most likely benign), and a CNV Table of the LGRs detected and indications of
genomic coordinates (chromosome, start, stop) and type (deletion or duplication).
4.4. Comparative Genomic Hybridization Array
A high resolution a-CGH analysis was performed on the patient’s genomic DNA. Briefly, genomic
DNA was digested, labeled and hybridized on the surface of the SurePrint G3 Human CGH Microarray
Kit, 1 × 1 M with 2.1 kb overall median probe spacing (1.8 kb in Refseq genes), according to the
manufacturer’s protocols already reported above (Agilent Technologies, Santa Clara, CA, USA).
Then, the microarray was scanned on an Agilent G2600D scanner, and image files were quantified
using Agilent’s Feature Extraction software (V11.5.1.1); data were visualized with Agilent’s Genomic
Work Bench Standard Edition (V7.0.4.0).
Supplementary Materials: Supplementary Materials can be found at www.mdpi.com/1422-0067/18/11/2487/s1.
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